AG Bostom, MA Carpenter, JW Kusek, AS Levey… - Circulation, 2011 - Am Heart Assoc From the Rhode Island Hospital, Providence (AGB, JLM); Department of Biostatistics, the University of North Carolina, Chapel Hill (MAC, LG-M.); National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (JWK); Tufts Medical Center, Boston, MA (ASL); ... Related articles - All 4 versions
MA Carpenter, A Bostom… - … Journal of Kidney …, 2011 - journals.elsevierhealth.com ... 2011. 52 Prevalence of CVD Risk Factors and their Treatment in Chronic, Stable Kidney Transplant Recipients in the FolicAcid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Myra A. Carpenter*: Affiliations. ... Cached - All 5 versions
SL O'Reilly, AP McGlynn, GR Wasson… - NSNZ & NSA 2006: …, 2011 - deakin.edu.au Background - Alterations in folate status are associated with colorectal carcinogenesis. Folate's role has been postulated to be either via prevention of changes in DNA methylation or uracil misincorporation. Objective - To investigate the effect of folic acid supplementation on ... Cached - All 2 versions
M Lucock - Journal of Evidence-Based Complementary & …, 2011 - chp.sagepub.com Abstract Mandatory and discretionary fortification with folic acid is eliminating deficiency of this vitamin. Blood levels of the vitamin have never been higher, with hematologic folate values commonly exceeding the upper range of calibration. The synthetic analog (pteroylmonoglutamic ... Related articles
[HTML] from imj.ieM Ward, J Hutton, R Mc Donnell, N Bachir… - Instructions for Authors, 2011 - imj.ie Promotion of folic acid to prevent neural Tube Defects (NTD) has been ongoing for ten years in Ireland, without a concomitant reduction in the total birth prevalence of NTD. The effectiveness of folic acid promotion as the sole means of primary prevention of NTD is therefore ... Cited by 22 - Related articles - Cached - All 3 versions